
Duchenne Muscular Dystrophy Drugs Global Market Report 2025
Description
Duchenne Muscular Dystrophy Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on duchenne muscular dystrophy drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Where is the largest and fastest growing market for duchenne muscular dystrophy drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The duchenne muscular dystrophy drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Markets Covered:1) By Drug Type: Exon Skipping Drugs; Corticosteroids; Gene Therapy; Other Drug Types
2) By Route Of Administration: Oral; Injectable
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) Exon Skipping Drugs: Eteplirsen; Golodirsen; Viltolarsen; Casimersen; Other Exon Skipping Therapies
2) Corticosteroids: Prednisone; Deflazacort; Other Corticosteroids
3) Gene Therapy: Micro-dystrophin Gene Therapy; CRISPR/Cas9-Based Gene Editing; Stem Cell-Based Gene Therapy; Other Gene Therapies
4) Other Drug Types: Utrophin Modulators; Anti-Inflammatory Agents; Antisense Oligonucleotides; Myostatin Inhibitors; Other Supportive Therapies
Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Bristol-Myers Squibb; Novartis AG; GSK plc; Eli Lilly and Company; Aurobindo Pharma Limited; Italfarmaco S.p.A; Sarepta Therapeutics Inc.; PTC Therapeutics Inc.; FibroGen Inc.; Wave Life Sciences Ltd.; Solid Biosciences Inc.; NS Pharma; Capricor Therapeutics Inc.; Santhera Pharmaceuticals; ReveraGen BioPharma; Antisense Therapeutics Limited; Catalyst Pharmaceuticals Inc.; EspeRare Foundation; Satellos Bioscience Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.
This report focuses on duchenne muscular dystrophy drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for duchenne muscular dystrophy drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The duchenne muscular dystrophy drugs market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Markets Covered:1) By Drug Type: Exon Skipping Drugs; Corticosteroids; Gene Therapy; Other Drug Types
2) By Route Of Administration: Oral; Injectable
3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Subsegments:
1) Exon Skipping Drugs: Eteplirsen; Golodirsen; Viltolarsen; Casimersen; Other Exon Skipping Therapies
2) Corticosteroids: Prednisone; Deflazacort; Other Corticosteroids
3) Gene Therapy: Micro-dystrophin Gene Therapy; CRISPR/Cas9-Based Gene Editing; Stem Cell-Based Gene Therapy; Other Gene Therapies
4) Other Drug Types: Utrophin Modulators; Anti-Inflammatory Agents; Antisense Oligonucleotides; Myostatin Inhibitors; Other Supportive Therapies
Companies Mentioned: Pfizer Inc.; Sanofi S.A.; Bristol-Myers Squibb; Novartis AG; GSK plc; Eli Lilly and Company; Aurobindo Pharma Limited; Italfarmaco S.p.A; Sarepta Therapeutics Inc.; PTC Therapeutics Inc.; FibroGen Inc.; Wave Life Sciences Ltd.; Solid Biosciences Inc.; NS Pharma; Capricor Therapeutics Inc.; Santhera Pharmaceuticals; ReveraGen BioPharma; Antisense Therapeutics Limited; Catalyst Pharmaceuticals Inc.; EspeRare Foundation; Satellos Bioscience Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Please Note: Report will be updated with the latest data and delivered to you within 3-5 working days of order.
Table of Contents
250 Pages
- 1. Executive Summary
- 2. Duchenne Muscular Dystrophy Drugs Market Characteristics
- 3. Duchenne Muscular Dystrophy Drugs Market Trends And Strategies
- 4. Duchenne Muscular Dystrophy Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
- 5. Global Duchenne Muscular Dystrophy Drugs Growth Analysis And Strategic Analysis Framework
- 5.1. Global Duchenne Muscular Dystrophy Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Duchenne Muscular Dystrophy Drugs Market Growth Rate Analysis
- 5.4. Global Duchenne Muscular Dystrophy Drugs Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Duchenne Muscular Dystrophy Drugs Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Duchenne Muscular Dystrophy Drugs Total Addressable Market (TAM)
- 6. Duchenne Muscular Dystrophy Drugs Market Segmentation
- 6.1. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Exon Skipping Drugs
- Corticosteroids
- Gene Therapy
- Other Drug Types
- 6.2. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral
- Injectable
- 6.3. Global Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- 6.4. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Exon Skipping Drugs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Eteplirsen
- Golodirsen
- Viltolarsen
- Casimersen
- Other Exon Skipping Therapies
- 6.5. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Prednisone
- Deflazacort
- Other Corticosteroids
- 6.6. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Gene Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Micro-dystrophin Gene Therapy
- CRISPR/Cas9-Based Gene Editing
- Stem Cell-Based Gene Therapy
- Other Gene Therapies
- 6.7. Global Duchenne Muscular Dystrophy Drugs Market, Sub-Segmentation Of Other Drug Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Utrophin Modulators
- Anti-Inflammatory Agents
- Antisense Oligonucleotides
- Myostatin Inhibitors
- Other Supportive Therapies
- 7. Duchenne Muscular Dystrophy Drugs Market Regional And Country Analysis
- 7.1. Global Duchenne Muscular Dystrophy Drugs Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Duchenne Muscular Dystrophy Drugs Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market
- 8.1. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 9. China Duchenne Muscular Dystrophy Drugs Market
- 9.1. China Duchenne Muscular Dystrophy Drugs Market Overview
- 9.2. China Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 10. India Duchenne Muscular Dystrophy Drugs Market
- 10.1. India Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11. Japan Duchenne Muscular Dystrophy Drugs Market
- 11.1. Japan Duchenne Muscular Dystrophy Drugs Market Overview
- 11.2. Japan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12. Australia Duchenne Muscular Dystrophy Drugs Market
- 12.1. Australia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13. Indonesia Duchenne Muscular Dystrophy Drugs Market
- 13.1. Indonesia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14. South Korea Duchenne Muscular Dystrophy Drugs Market
- 14.1. South Korea Duchenne Muscular Dystrophy Drugs Market Overview
- 14.2. South Korea Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15. Western Europe Duchenne Muscular Dystrophy Drugs Market
- 15.1. Western Europe Duchenne Muscular Dystrophy Drugs Market Overview
- 15.2. Western Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16. UK Duchenne Muscular Dystrophy Drugs Market
- 16.1. UK Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17. Germany Duchenne Muscular Dystrophy Drugs Market
- 17.1. Germany Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18. France Duchenne Muscular Dystrophy Drugs Market
- 18.1. France Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19. Italy Duchenne Muscular Dystrophy Drugs Market
- 19.1. Italy Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20. Spain Duchenne Muscular Dystrophy Drugs Market
- 20.1. Spain Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21. Eastern Europe Duchenne Muscular Dystrophy Drugs Market
- 21.1. Eastern Europe Duchenne Muscular Dystrophy Drugs Market Overview
- 21.2. Eastern Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22. Russia Duchenne Muscular Dystrophy Drugs Market
- 22.1. Russia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23. North America Duchenne Muscular Dystrophy Drugs Market
- 23.1. North America Duchenne Muscular Dystrophy Drugs Market Overview
- 23.2. North America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24. USA Duchenne Muscular Dystrophy Drugs Market
- 24.1. USA Duchenne Muscular Dystrophy Drugs Market Overview
- 24.2. USA Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25. Canada Duchenne Muscular Dystrophy Drugs Market
- 25.1. Canada Duchenne Muscular Dystrophy Drugs Market Overview
- 25.2. Canada Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26. South America Duchenne Muscular Dystrophy Drugs Market
- 26.1. South America Duchenne Muscular Dystrophy Drugs Market Overview
- 26.2. South America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27. Brazil Duchenne Muscular Dystrophy Drugs Market
- 27.1. Brazil Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28. Middle East Duchenne Muscular Dystrophy Drugs Market
- 28.1. Middle East Duchenne Muscular Dystrophy Drugs Market Overview
- 28.2. Middle East Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29. Africa Duchenne Muscular Dystrophy Drugs Market
- 29.1. Africa Duchenne Muscular Dystrophy Drugs Market Overview
- 29.2. Africa Duchenne Muscular Dystrophy Drugs Market, Segmentation By Drug Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Duchenne Muscular Dystrophy Drugs Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Duchenne Muscular Dystrophy Drugs Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 30. Duchenne Muscular Dystrophy Drugs Market Competitive Landscape And Company Profiles
- 30.1. Duchenne Muscular Dystrophy Drugs Market Competitive Landscape
- 30.2. Duchenne Muscular Dystrophy Drugs Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Bristol-Myers Squibb Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. GSK plc Overview, Products and Services, Strategy and Financial Analysis
- 31. Duchenne Muscular Dystrophy Drugs Market Other Major And Innovative Companies
- 31.1. Eli Lilly and Company
- 31.2. Aurobindo Pharma Limited
- 31.3. Italfarmaco S.p.A
- 31.4. Sarepta Therapeutics Inc.
- 31.5. PTC Therapeutics Inc.
- 31.6. FibroGen Inc.
- 31.7. Wave Life Sciences Ltd.
- 31.8. Solid Biosciences Inc.
- 31.9. NS Pharma
- 31.10. Capricor Therapeutics Inc.
- 31.11. Santhera Pharmaceuticals
- 31.12. ReveraGen BioPharma
- 31.13. Antisense Therapeutics Limited
- 31.14. Catalyst Pharmaceuticals Inc.
- 31.15. EspeRare Foundation
- 32. Global Duchenne Muscular Dystrophy Drugs Market Competitive Benchmarking And Dashboard
- 33. Key Mergers And Acquisitions In The Duchenne Muscular Dystrophy Drugs Market
- 34. Recent Developments In The Duchenne Muscular Dystrophy Drugs Market
- 35. Duchenne Muscular Dystrophy Drugs Market High Potential Countries, Segments and Strategies
- 35.1 Duchenne Muscular Dystrophy Drugs Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Duchenne Muscular Dystrophy Drugs Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Duchenne Muscular Dystrophy Drugs Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
- 36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.